SEC INSIDER TRANSACTIONS

COLGATE PALMOLIVE CO (CL) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

CL · COLGATE PALMOLIVE CO

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Stale snapshot · Covered: filings 2026-10-15 to 2026-11-13 · 5 filings · fetched 2026-11-13T17:00:23Z

View six-calendar-month insider history →

Recent reported activity

0purchase rows on this page

5sale rows on this page

11matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-10Filed 2026-11-12	Malcolm GregoryOfficer · EVP and Controller Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	S Sale (market/private)Common Stock · Non-derivative	4,100D	97.97	Direct	Form 4 ↗0001225208-26-008888
2026-11-05Filed 2026-11-09	NORRINGTON LORRIE MDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan. F3 Option became exercisable in one-third increments beginning on the first anniversary of the May 13, 2019 grant date. References: F1, F3	M Exercise / conversionStock Option (Right to Buy) · Derivative	4,170D	0	Direct	Form 4 ↗0001225208-26-008777
2026-11-05Filed 2026-11-09	NORRINGTON LORRIE MDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan. F3 Option became exercisable in one-third increments beginning on the first anniversary of the May 13, 2019 grant date. References: F2	S Sale (market/private)Common Stock · Non-derivative	4,170D	99.3101	Direct	Form 4 ↗0001225208-26-008777
2026-11-05Filed 2026-11-09	NORRINGTON LORRIE MDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan. F3 Option became exercisable in one-third increments beginning on the first anniversary of the May 13, 2019 grant date. References: F1	M Exercise / conversionCommon Stock · Non-derivative	4,170A	71.56	Direct	Form 4 ↗0001225208-26-008777
2026-11-05Filed 2026-11-06	Wallace Noel R.Director · Officer · Chairman, President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $100.01 to $100.51, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. References: F1	S Sale (market/private)Common Stock · Non-derivative	20,000D	100.2581	Direct	Form 4 ↗0001225208-26-008755
2026-11-04Filed 2026-11-06	Hazlin JohnOfficer · Chief Growth Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.93 to $99.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2021 grant date. References: F1, F4	M Exercise / conversionStock Option (Right to Buy) · Derivative	23,376D	0	Direct	Form 4 ↗0001225208-26-008751
2026-11-04Filed 2026-11-06	Hazlin JohnOfficer · Chief Growth Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.93 to $99.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2021 grant date. References: F2, F3	S Sale (market/private)Common Stock · Non-derivative	23,376D	99.1479	Direct	Form 4 ↗0001225208-26-008751
2026-11-04Filed 2026-11-06	Hazlin JohnOfficer · Chief Growth Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.93 to $99.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2021 grant date. References: F1	M Exercise / conversionCommon Stock · Non-derivative	23,376A	77.04	Direct	Form 4 ↗0001225208-26-008751
2026-11-04Filed 2026-11-06	Tsourapas PanagiotisOfficer · COO, CD, EMEA, APac, Skin Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.585 to $98.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 This amount includes 2,336 shares that were previously reported as directly beneficially owned. F5 Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date. References: F1, F5	M Exercise / conversionStock Option (Right to Buy) · Derivative	19,938D	0	Direct	Form 4 ↗0001225208-26-008752
2026-11-04Filed 2026-11-06	Tsourapas PanagiotisOfficer · COO, CD, EMEA, APac, Skin Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.585 to $98.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 This amount includes 2,336 shares that were previously reported as directly beneficially owned. F5 Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date. References: F2, F3	S Sale (market/private)Common Stock · Non-derivative	19,938D	98.7415	Direct	Form 4 ↗0001225208-26-008752
2026-11-04Filed 2026-11-06	Tsourapas PanagiotisOfficer · COO, CD, EMEA, APac, Skin Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Exercise of stock options awarded under the issuer's incentive compensation plan. F2 Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan and the related tax withholding. F3 Weighted average price, as these shares were sold in multiple transactions at prices ranging from $98.585 to $98.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 This amount includes 2,336 shares that were previously reported as directly beneficially owned. F5 Option became exercisable in one-third increments beginning on the first anniversary of the September 10, 2020 grant date. References: F1	M Exercise / conversionCommon Stock · Non-derivative	19,938A	76.41	Direct	Form 4 ↗0001225208-26-008752

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.